Determined to realize a future in which people with cancer live longer and better than ever before

Syndax

4Q20 EARNINGS PRESENTATION

Forward-looking statements disclosure

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding future operations, financial results and the financial condition of Syndax Pharmaceuticals, Inc. ("Syndax" or the "Company"), including financial position, strategy and plans, the progress, timing, clinical development and scope of clinical trials and the reporting of clinical data for Syndax's product candidates, and Syndax's expectations for liquidity and future operations, are forward-looking statements. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected, changes in expected or existing competition, failure of our collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Moreover, Syndax operates in a very competitive and rapidly changing environment. Other factors that may cause our actual results to differ from current expectations are discussed in Syndax's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. New risks emerge from time to time. It is not possible for Syndax's management to predict all risks, nor can Syndax assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this presentation may not occur and actual results could differ materially and adversely from those anticipated or implied. Except as required by law, neither Syndax nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. Syndax undertakes no obligation to update publicly any forward-looking statements for any reason after the date of this presentation to conform these statements to actual results or to changes in Syndax's expectations.

Syndax pipeline targets indications with significant unmet need

Menin Inhibitor Program (SNDX-5613)

- Target validated for acute leukemias
- Ph 1 data expected late 1Q/early 2Q
- Ph 2 initiation expected 2Q
- Accelerated path to approval

Anti-CSF-1R Program (Axatilimab)

- Macrophage driven diseases
- Ph 1 data validates target for cGVHD, additional inflammatory / fibrotic opportunities
- Pivotal trial ongoing (AGAVE-201)

Development Opportunities

- Focused on expanding clinical pipeline through development and in-licensing

SNDX-5613: Breakthrough targeted therapy for acute leukemia

Advantages

- Strong target validation
- Precise patient selection
- Big effect in small studies
- Molecular markers of disease status
- Potential for rapid regulatory path







Science Contents News Careers Journals

CANCER

Therapeutic targeting of preleukemia cells in a mouse model of *NPM1* mutant acute myeloid leukemia

Cancer Cell

Article

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of *MLL*-Rearranged Leukemia

Graphical Abstract

Authors

Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey, ..., Gerard M. McGeehan, Richard B. Lock, Scott A. Armstrong

Correspondence

scott_armstrong@dfci.harvard.edu

In Brief

Krivtsov et al. develop a selective and orally bioavailable small-molecule inhibitor targeting the Menin-MLL interaction, which suppresses a subset of MLL fusion target genes and significantly improves survival in PDX models of MLL-rearranged leukemia.

Highlights

- A selective, orally bioavailable Menin-MLL inhibitor, VTP50469, is developed
- Displacement of Menin from chromatin leads to loss of MLL from specific loci
- Treatment with VTP50469 leads to suppression of a subset of MLL fusion target genes
- Treatment with VTP50469 improves survival in PDX models of *MLL*-r ALL

Krivtsov et al., 2019, Cancer Cell 36, 660–673
December 9, 2019 © 2019 Elsevier Inc.
https://doi.org/10.1016/j.ccell.2019.11.001

CellPress

AUGMENT-101: Ph 1/2 trial testing SNDX-5613 in MLL-r and NPM1 acute leukemia



Ph 1 data late 1Q/early 2Q, Ph 2 initiation expected in 2Q

** Allows patients ≥ 30 days of age; MLL-r - mixed lineage leukemia rearranged; NPM = nucleophosmin*; CR = Complete response; CRh = CR with partial hematologic recovery

Multiple commercial opportunities in acute leukemias

- **Potential fast to market regulatory path in R/R disease**
- **Subsequent approvals prioritized by medical need and commercial opportunity**
- **Collaborate and broaden utilization through combo and investigator-initiated trials**



AGAVE-201: global pivotal trial for Axatilimab, a CSF-1R mAB, in chronic GVHD

Inclusion criteria:

- 6 years and older
- Recurrent or refractory active cGVHD after at least 2 lines of systemic therapy



Primary Endpoint: Objective Response Rate (ORR) by 2014 NIH GVHD Criteria

Key Secondaries: Duration of response, improvement in modified Lee Symptom Scale

Proven ability to build the pipeline

Business development continues to be a core strength of our business

Clinical development leadership enables competitive advantage

Established relationships enhance identification and access to quality assets

From UCB

Axatilimab

From Allergan/Vitae

Menin-MLL inhibitors



Financial highlights and FY 2021 financial guidance

Ticker	SNDX (NASDAQ)
Cash and short-term investments (at December 31, 2020)	$293.1 million
Shares Outstanding* (at December 31, 2020)	51.4 million

1Q and 2021 Operating Expense Guidance		
	1Q 2021	FY 2021
Research and Development	$25-30 million	$90-100 million
Total Operating Expenses^	$30-35 million	$110-120 million

* *Includes 47.9 million common shares and pre-funded warrants to purchase 3.6 million common shares;*
^ *Includes ~$2.0 million non-cash stock compensation expense per quarter*

Thank you. Questions?

Syndax